Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction

Thrombosis and Haemostasis

Volumn 76, Issue 3, 1996, Pages 417-421

  Ralliais, Loukianos S ^a   Megalou, Ageliki A ^a   Papageorgakis, Nikos H ^a   Trikas, Athanasios G ^a   Chatzidimitriou, Grammatiki I ^b   Tsitouris, George K ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; APOLIPOPROTEIN; APOLIPOPROTEIN B; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HEREDITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NORMAL HUMAN; ONSET AGE; PRIORITY JOURNAL; PROGENY; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029826769     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650593     Document Type: Article

References (43)

1. Chmielwska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator inhibitor in plasma. Thromb Res 1983; 31: 427-36.
2. Chandler WL. A kinetic model of the circulatory regulation of tissue plasminogen activator. Thromb Haemost 1991; 66: 321-8.
3. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
4. Barbash Gl, Hod H, Roth A, Miller HI, Rath S, Harzahav Y, Modan M, Zivelin A, Laniado S, Seligsohn U. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989; 64: 1231-5.
5. Levi M, Biemond BJ, Van Zonneveld AJ, Ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor 1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-12.
6. Chomiki N, Henry M, Alessi MC, Anfosso F, Julian-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994; 72: 44-53.
7. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1090-100.
8. Holman RL, McGill HC Jr, Strong JP, Geer JC. The natural history of atherosclerosis. The early aortic lesions as seen in the middle of 20th century. Am J Pathol 1958; 34: 209-35.
9. Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea: Preliminary report. JAMA 1953; 152: 1090-3.
10. Rissanen AM, Nikkila EA. Aggregation of coronary risk factors in families of men with fatal and non-fatal coronary heart disease. Br Heart J 1979; 42: 373-80.
11. Ten Kate LP, Boman H, Daiger SP, Motulsky AG. Familial aggregation of coronary heart disease and its relation to known genetic risk factors. Am J Cardiol 1982; 50: 945-53.
12. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
13. Bara L, Nicaud V, Tiret L, Cambien F, Samama MM. Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAH in European offspring - The EARS Study. Thromb Haemost 1994; 71: 434-40.
14. Paramo JA, Colucci M, Collen D, Van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 573-4.
15. Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77-82.
16. Huber K, Resch I, Stefenelli T, Lang I, Probst P, Kaindl F, Binder BR. Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis. Thromb Haemosl 1990; 63: 336-9.
17. Thompson SG, Van De Loo JCW. ECAT Angina Pectoris Study. Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
18. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 1995; 73: 374-9.
19. Klinger K, Winqvist R, Riccio A, Andreasen PA, Sartorio R, Nielson LS, Stuart N, Stanislovitis P, Watkins P, Douglas R, et al. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sci USA 1987; 84: 8548-52.
20. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-90.
21. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allelespecific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci 1995, 92: 1851-5.
22. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC study. Circulation 1995, 91: 284-90.
23. Ross R. The process of atherogenesis - cellular and molecular interaction: from experimental animal models to humans. Diabetologia 1992; 35: (suppl. 2) S34-S40.
24. Emeis J, Kooistra T. Interleukin-1 and lipopolysaccharide induce a fast acting inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-6.
25. de Boer JP, Abbink JJ, Brouwer MC, Meijer C, Roem S, Voorn GP, Lambers JWJ, van Mouric JA, Hack CE. PAI-1 synthesis in the human hepatoma cell line hep G2 is increased by cytokines - evidence that the liver contributes to acute phase behaviour of PAI-1. Thromb Haemost 1991; 65: 181-5.
26. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur H Journal 1993; 14: 8-17.
27. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
28. Caron P, Bennet A, Camare R, Louvet JP, Boneu B, Sié P. Plasminogen activator inhibitor in plasma is related to testosterone in men. Metabolism 1989; 38: 1010-5.
29. Scarabin PY, Bonithon-Kopp C, Bara L, Guize L, Samama M. Relationship between plasminogen activator inhibitor activity and menopausal status. Fibrinolysis 1990; 4: 233-6.
30. Sizonenko PC. Endocrinology in preadolescents and adolescents. Part I: hormonal changes during normal puberty. Am J Dis Child 1978, 132: 704-12.
31. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Allan C. Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diab Metab 1987; 13: 331-6.
32. Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263-8.
33. Gray RP, Mohamed-Ali V, Patterson DLH, Yudkin JS. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction. Thromb Haemost 1995; 73: 261-7.
34. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very low density lipoproteins. Arteriosclerosis 1990; 10: 1067-73.
35. Mussoni L, Maderna F, Camera M, Bernini F, Sironi L, Sirtori M, Tremoli E. Atherogenic lipoproteins and release of plasminogen activator inhibitor 1 (PAI-1) by endothelial cells. Fibrinolysis 1990; (suppl. 2) 79-81.
36. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, JuhanVague I. Stimulating effect of oxidized low density lipoprotein on plasminogen activator inhibitor 1 synthesis by endothelial cells. Arterioscler Thromb 1991; 11: 1821-9.
37. Etingin O, Hajjar D, Hajjar K, Harpel P, Nachman R. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: A potential mechanism in thrombogenesis. J Biol Chem 1991; 266: 2459-65.
38. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993; 70: 138-43.
39. Francis RB, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988; 115: 776-80.
40. Sanchez-Bayle M, Cocho P, Baeza J, Vila S. Fibrinogen as a cardiovascular risk factor in Spanish children and adolescents. Am Heart J 1993; 126: 322-6.
41. Rallidis L, Papageorgakis N, Megalou A, Anagnostou E, Chatzidimitriou G, Tsitouris G. Fibrinogen in the offspring of men with premature coronary artery disease. Eur Heart J 1995; 16: 1814-8.
42. Thompson WD, Smith EB. Atherosclerosis and the coagulation system. J Pathol 1989; 159: 97-106.
43. Bini A, Fenoglio JJ, Mesa-Tejada R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin and fibrin(ogen) degradation products in atherosclerosis: Use of monoclonal antibodies. Arteriosclerosis 1989; 9: 109-21.